Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.40 |
| ▸ | GABRD | O14764 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.40 |
| ▸ | GABRE | P78334 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230832 | 0.86 | PTGER1 (0.44) | KDM4ESMN1; SMN2BRD4ALDH1A1NPC1 | |
| SCHEMBL1809016 | 0.77 | KDM4E (0.48) | KDM4EPOLBALOX5JAK2JAK3 | |
| SCHEMBL20751064 | 0.76 | POLB (0.51) | KDM4EPOLBKMT2AMEN1HSP90AA1 | |
| SCHEMBL31601642 | 0.76 | KMT2A (0.47) | KDM4EKMT2AMEN1HSP90AA1GABRG2 | |
| SCHEMBL25037159 | 0.76 | KMT2A (0.47) | KDM4EKMT2AMEN1HSP90AA1GABRG2 | |
| SCHEMBL6231126 | 0.75 | IKBKE (0.42) | POLBSMN1; SMN2BRD4MAPTRAB9A | |
| SCHEMBL30038944 | 0.73 | MEN1 (0.45) | KDM4EKMT2AMEN1HSP90AA1GABRG2 | |
| SCHEMBL25035262 | 0.72 | GABRA1 (0.46) | KMT2AMEN1HSP90AA1GABRG2GABRB3 | |
| SCHEMBL21750060 | 0.71 | GABRA1 (0.44) | KDM4EKMT2AMEN1HSP90AA1GABRG2 | |
| SCHEMBL20307754 | 0.70 | KDM4E (0.53) | KDM4EPOLBKMT2AMEN1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483266-B1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-7304072-B2 | E.g.,cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases, respiratory and urogenital disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-20050032820-A1 | Novel spiro compounds | MSD K.K. (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1483266-A1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076443-A1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032820-A1 | Novel spiro compounds | NR3C2, GPR119, NPY2R | KDM4E 3341/4885POLB 3339/4885ALOX5 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.